Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Early research (Phase 1)Study completedNCT00104962
What this trial is testing

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Who this might be right for
Childhood Myelodysplastic Syndromesde Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic Syndromes+6 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Ended earlyNCT00104806
What this trial is testing

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Wake Forest University Health Sciences 5
Testing effectiveness (Phase 2)Study completedNCT00054327
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndromes+1 more
Case Comprehensive Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT00005853
What this trial is testing

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00619645
What this trial is testing

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of California, Davis 8
Testing effectiveness (Phase 2)Ended earlyNCT00398047
What this trial is testing

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Wake Forest University Health Sciences 3
Testing effectiveness (Phase 2)Ended earlyNCT00005641
What this trial is testing

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+2 more
H. Lee Moffitt Cancer Center and Research Institute
Testing effectiveness (Phase 2)Ended earlyNCT00119366
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+14 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00731328
What this trial is testing

Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesNonmalignant Neoplasm+1 more
Asan Medical Center 15
Early research (Phase 1)Study completedNCT00005845
What this trial is testing

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Who this might be right for
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic Syndromes+5 more
National Cancer Institute (NCI) 65
Testing effectiveness (Phase 2)Study completedNCT01012492
What this trial is testing

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Who this might be right for
AMLALLUndifferentiated Leukemia+9 more
Boston Children's Hospital 11
Testing effectiveness (Phase 2)Study completedNCT00397813
What this trial is testing

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Who this might be right for
Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndrome+11 more
Fred Hutchinson Cancer Center 77
Testing effectiveness (Phase 2)Study completedNCT00005622
What this trial is testing

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMultiple Myeloma and Malignant Plasma Cell Neoplasms+2 more
H. Lee Moffitt Cancer Center and Research Institute 72
Early research (Phase 1)Study completedNCT00988715
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic Syndrome+6 more
Fred Hutchinson Cancer Center 17
Large-scale testing (Phase 3)UnknownNCT00002926
What this trial is testing

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Who this might be right for
LeukemiaMyelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC 80
18